Oncology Based In-vitro CRO - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB510242903

Publication Date:

October 28, 2024

Pages:

115

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Preclinical research refers to before testing a drug in people, researchers must find out whether it has the potential to cause serious harm, also called toxicity. A Preclinical CRO, or preclinical contract research organization, provides the experience, knowledge, and skill required to take a pharmaceutical product or medical device from the drawing board to distribution. This journey entails a plethora of activities that involve scientists, medical personnel, administrators, governmental and industry liaisons, marketing experts, and a host of other technical and creative individuals. Rarely is this unique combination of credentials and craft already present within a sponsoring organization. The CRO industry emerged to fill this much-needed role, to provide the expertise required to bring a pharmaceutical product or medical device into the marketplace as quickly and smoothly as possible. This report focus on Oncology Based In-vitro CRO.
The global market for Oncology Based In-vitro CRO was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Oncology Based In-vitro CRO was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Oncology Based In-vitro CRO was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Oncology Based In-vitro CRO was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Oncology Based In-vitro CRO include Crown Bioscience, Charles River Laboratory, ICON Plc., Eurofins Scientific, Taconic Biosciences, Covance, EVOTEC, The Jackson Laboratory and Wuxi AppTec., etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Oncology Based In-vitro CRO, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Oncology Based In-vitro CRO by region & country, by Type, and by Application.
The Oncology Based In-vitro CRO market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oncology Based In-vitro CRO.
麻豆原创 Segmentation
By Company
Crown Bioscience
Charles River Laboratory
ICON Plc.
Eurofins Scientific
Taconic Biosciences
Covance
EVOTEC
The Jackson Laboratory
Wuxi AppTec.
MI Bioresearch, Inc.
Champion Oncology, Inc.
Xentech
Segment by Type:
Blood Cancer
Solid Tumors
Other
Segment by Application
Pharmaceutical & Biopharmaceutical Industries
Medical Device Companies
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Oncology Based In-vitro CRO manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Oncology Based In-vitro CRO in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Oncology Based In-vitro CRO in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Oncology Based In-vitro CRO Product Introduction
1.2 Global Oncology Based In-vitro CRO 麻豆原创 Size Forecast
1.3 Oncology Based In-vitro CRO 麻豆原创 Trends & Drivers
1.3.1 Oncology Based In-vitro CRO Industry Trends
1.3.2 Oncology Based In-vitro CRO 麻豆原创 Drivers & Opportunity
1.3.3 Oncology Based In-vitro CRO 麻豆原创 Challenges
1.3.4 Oncology Based In-vitro CRO 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Oncology Based In-vitro CRO Players Revenue Ranking (2023)
2.2 Global Oncology Based In-vitro CRO Revenue by Company (2019-2024)
2.3 Key Companies Oncology Based In-vitro CRO Manufacturing Base Distribution and Headquarters
2.4 Key Companies Oncology Based In-vitro CRO Product Offered
2.5 Key Companies Time to Begin Mass Production of Oncology Based In-vitro CRO
2.6 Oncology Based In-vitro CRO 麻豆原创 Competitive Analysis
2.6.1 Oncology Based In-vitro CRO 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Oncology Based In-vitro CRO Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncology Based In-vitro CRO as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Blood Cancer
3.1.2 Solid Tumors
3.1.3 Other
3.2 Global Oncology Based In-vitro CRO Sales Value by Type
3.2.1 Global Oncology Based In-vitro CRO Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Oncology Based In-vitro CRO Sales Value, by Type (2019-2030)
3.2.3 Global Oncology Based In-vitro CRO Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Pharmaceutical & Biopharmaceutical Industries
4.1.2 Medical Device Companies
4.1.3 Others
4.2 Global Oncology Based In-vitro CRO Sales Value by Application
4.2.1 Global Oncology Based In-vitro CRO Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Oncology Based In-vitro CRO Sales Value, by Application (2019-2030)
4.2.3 Global Oncology Based In-vitro CRO Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Oncology Based In-vitro CRO Sales Value by Region
5.1.1 Global Oncology Based In-vitro CRO Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Oncology Based In-vitro CRO Sales Value by Region (2019-2024)
5.1.3 Global Oncology Based In-vitro CRO Sales Value by Region (2025-2030)
5.1.4 Global Oncology Based In-vitro CRO Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Oncology Based In-vitro CRO Sales Value, 2019-2030
5.2.2 North America Oncology Based In-vitro CRO Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Oncology Based In-vitro CRO Sales Value, 2019-2030
5.3.2 Europe Oncology Based In-vitro CRO Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Oncology Based In-vitro CRO Sales Value, 2019-2030
5.4.2 Asia Pacific Oncology Based In-vitro CRO Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Oncology Based In-vitro CRO Sales Value, 2019-2030
5.5.2 South America Oncology Based In-vitro CRO Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Oncology Based In-vitro CRO Sales Value, 2019-2030
5.6.2 Middle East & Africa Oncology Based In-vitro CRO Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Oncology Based In-vitro CRO Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Oncology Based In-vitro CRO Sales Value
6.3 United States
6.3.1 United States Oncology Based In-vitro CRO Sales Value, 2019-2030
6.3.2 United States Oncology Based In-vitro CRO Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Oncology Based In-vitro CRO Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Oncology Based In-vitro CRO Sales Value, 2019-2030
6.4.2 Europe Oncology Based In-vitro CRO Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Oncology Based In-vitro CRO Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Oncology Based In-vitro CRO Sales Value, 2019-2030
6.5.2 China Oncology Based In-vitro CRO Sales Value by Type (%), 2023 VS 2030
6.5.3 China Oncology Based In-vitro CRO Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Oncology Based In-vitro CRO Sales Value, 2019-2030
6.6.2 Japan Oncology Based In-vitro CRO Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Oncology Based In-vitro CRO Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Oncology Based In-vitro CRO Sales Value, 2019-2030
6.7.2 South Korea Oncology Based In-vitro CRO Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Oncology Based In-vitro CRO Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Oncology Based In-vitro CRO Sales Value, 2019-2030
6.8.2 Southeast Asia Oncology Based In-vitro CRO Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Oncology Based In-vitro CRO Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Oncology Based In-vitro CRO Sales Value, 2019-2030
6.9.2 India Oncology Based In-vitro CRO Sales Value by Type (%), 2023 VS 2030
6.9.3 India Oncology Based In-vitro CRO Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Crown Bioscience
7.1.1 Crown Bioscience Profile
7.1.2 Crown Bioscience Main Business
7.1.3 Crown Bioscience Oncology Based In-vitro CRO Products, Services and Solutions
7.1.4 Crown Bioscience Oncology Based In-vitro CRO Revenue (US$ Million) & (2019-2024)
7.1.5 Crown Bioscience Recent Developments
7.2 Charles River Laboratory
7.2.1 Charles River Laboratory Profile
7.2.2 Charles River Laboratory Main Business
7.2.3 Charles River Laboratory Oncology Based In-vitro CRO Products, Services and Solutions
7.2.4 Charles River Laboratory Oncology Based In-vitro CRO Revenue (US$ Million) & (2019-2024)
7.2.5 Charles River Laboratory Recent Developments
7.3 ICON Plc.
7.3.1 ICON Plc. Profile
7.3.2 ICON Plc. Main Business
7.3.3 ICON Plc. Oncology Based In-vitro CRO Products, Services and Solutions
7.3.4 ICON Plc. Oncology Based In-vitro CRO Revenue (US$ Million) & (2019-2024)
7.3.5 Eurofins Scientific Recent Developments
7.4 Eurofins Scientific
7.4.1 Eurofins Scientific Profile
7.4.2 Eurofins Scientific Main Business
7.4.3 Eurofins Scientific Oncology Based In-vitro CRO Products, Services and Solutions
7.4.4 Eurofins Scientific Oncology Based In-vitro CRO Revenue (US$ Million) & (2019-2024)
7.4.5 Eurofins Scientific Recent Developments
7.5 Taconic Biosciences
7.5.1 Taconic Biosciences Profile
7.5.2 Taconic Biosciences Main Business
7.5.3 Taconic Biosciences Oncology Based In-vitro CRO Products, Services and Solutions
7.5.4 Taconic Biosciences Oncology Based In-vitro CRO Revenue (US$ Million) & (2019-2024)
7.5.5 Taconic Biosciences Recent Developments
7.6 Covance
7.6.1 Covance Profile
7.6.2 Covance Main Business
7.6.3 Covance Oncology Based In-vitro CRO Products, Services and Solutions
7.6.4 Covance Oncology Based In-vitro CRO Revenue (US$ Million) & (2019-2024)
7.6.5 Covance Recent Developments
7.7 EVOTEC
7.7.1 EVOTEC Profile
7.7.2 EVOTEC Main Business
7.7.3 EVOTEC Oncology Based In-vitro CRO Products, Services and Solutions
7.7.4 EVOTEC Oncology Based In-vitro CRO Revenue (US$ Million) & (2019-2024)
7.7.5 EVOTEC Recent Developments
7.8 The Jackson Laboratory
7.8.1 The Jackson Laboratory Profile
7.8.2 The Jackson Laboratory Main Business
7.8.3 The Jackson Laboratory Oncology Based In-vitro CRO Products, Services and Solutions
7.8.4 The Jackson Laboratory Oncology Based In-vitro CRO Revenue (US$ Million) & (2019-2024)
7.8.5 The Jackson Laboratory Recent Developments
7.9 Wuxi AppTec.
7.9.1 Wuxi AppTec. Profile
7.9.2 Wuxi AppTec. Main Business
7.9.3 Wuxi AppTec. Oncology Based In-vitro CRO Products, Services and Solutions
7.9.4 Wuxi AppTec. Oncology Based In-vitro CRO Revenue (US$ Million) & (2019-2024)
7.9.5 Wuxi AppTec. Recent Developments
7.10 MI Bioresearch, Inc.
7.10.1 MI Bioresearch, Inc. Profile
7.10.2 MI Bioresearch, Inc. Main Business
7.10.3 MI Bioresearch, Inc. Oncology Based In-vitro CRO Products, Services and Solutions
7.10.4 MI Bioresearch, Inc. Oncology Based In-vitro CRO Revenue (US$ Million) & (2019-2024)
7.10.5 MI Bioresearch, Inc. Recent Developments
7.11 Champion Oncology, Inc.
7.11.1 Champion Oncology, Inc. Profile
7.11.2 Champion Oncology, Inc. Main Business
7.11.3 Champion Oncology, Inc. Oncology Based In-vitro CRO Products, Services and Solutions
7.11.4 Champion Oncology, Inc. Oncology Based In-vitro CRO Revenue (US$ Million) & (2019-2024)
7.11.5 Champion Oncology, Inc. Recent Developments
7.12 Xentech
7.12.1 Xentech Profile
7.12.2 Xentech Main Business
7.12.3 Xentech Oncology Based In-vitro CRO Products, Services and Solutions
7.12.4 Xentech Oncology Based In-vitro CRO Revenue (US$ Million) & (2019-2024)
7.12.5 Xentech Recent Developments
8 Industry Chain Analysis
8.1 Oncology Based In-vitro CRO Industrial Chain
8.2 Oncology Based In-vitro CRO Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Oncology Based In-vitro CRO Sales Model
8.5.2 Sales Channel
8.5.3 Oncology Based In-vitro CRO Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Crown Bioscience
Charles River Laboratory
ICON Plc.
Eurofins Scientific
Taconic Biosciences
Covance
EVOTEC
The Jackson Laboratory
Wuxi AppTec.
MI Bioresearch, Inc.
Champion Oncology, Inc.
Xentech

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.